{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:57:46Z","timestamp":1773867466555,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.pnpbp.2013.09.015","type":"journal-article","created":{"date-parts":[[2013,10,2]],"date-time":"2013-10-02T13:31:34Z","timestamp":1380720694000},"page":"207-212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Treatment of acute schizophrenia with paliperidone ER: Predictors for treatment response and benzodiazepine use"],"prefix":"10.1016","volume":"48","author":[{"given":"Stephan","family":"Heres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liana","family":"Don","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miroslav","family":"Herceg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leszek","family":"Bidzan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Siracusano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentinas","family":"Maciulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjolein","family":"Lahaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Schreiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2013.09.015_bb0005","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/archpsyc.60.12.1228","article-title":"Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected","volume":"60","author":"Agid","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.09.015_bb0010","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1744-859X-10-12","article-title":"Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial","volume":"10","author":"Alphs","year":"2011","journal-title":"Ann Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.09.015_bb0015","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association (APA)","year":"1994"},{"key":"10.1016\/j.pnpbp.2013.09.015_bb0020","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1177\/070674378903400716","article-title":"Drug therapy in schizophrenia \u2014 variability of outcome and prediction of response","volume":"34","author":"Awad","year":"1989","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.09.015_bb0025","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1600-0447.1990.tb03070.x","article-title":"Predicting neuroleptic response from a combination of multilevel variables in acute schizophrenic patients","volume":"82","author":"Bartk\u00f3","year":"1990","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.pnpbp.2013.09.015_bb0030","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.psychres.2009.03.003","article-title":"Clinical predictors of response to olanzapine or risperidone during acute episode of schizophrenia","volume":"179","author":"Brousse","year":"2010","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pnpbp.2013.09.015_bb0035","doi-asserted-by":"crossref","first-page":"587","DOI":"10.4088\/JCP.09m05564yel","article-title":"A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder","volume":"71","author":"Canuso","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.09.015_bb0040","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/01.jcp.0000246211.95905.8c","article-title":"Optimizing early prediction for antipsychotic response in schizophrenia","volume":"26","author":"Change","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2013.09.015_bb0045","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.schres.2009.06.001","article-title":"Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods","volume":"113","author":"Chen","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2013.09.015_bb0055","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jpsychires.2006.05.002","article-title":"Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables","volume":"41","author":"Crespo-Facorro","year":"2007","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.pnpbp.2013.09.015_bb0060","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.schres.2007.03.003","article-title":"Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study","volume":"93","author":"Davidson","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2013.09.015_bb0070","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.4088\/JCP.v67n1106","article-title":"Remission in first-episode psychosis: predictor variables and symptom improvement patterns","volume":"66","author":"Emsley","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.09.015_bb0075","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.schres.2006.09.013","article-title":"Early Psychosis Global Working Group. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates","volume":"89","author":"Emsley","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2013.09.015_bb0065","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/YIC.0b013e328314e1f3","article-title":"Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies","volume":"23","author":"Emsley","year":"2008","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2013.09.015_bb0080","series-title":"ECDEU assessment manual for psychopharmacology","first-page":"218","article-title":"Clinical global impressions","author":"Guy","year":"1976"},{"issue":"Suppl. 12","key":"10.1016\/j.pnpbp.2013.09.015_bb0085","first-page":"20","article-title":"The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders","volume":"64","author":"Kane","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.09.015_bb0090","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2013.09.015_bb0095","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.schres.2008.02.021","article-title":"Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia","volume":"102","author":"Kinon","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2013.09.015_bb0100","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4088\/JCP.v68n0301","article-title":"Early prediction of antipsychotic nonresponse among patients with schizophrenia","volume":"68","author":"Leucht","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.09.015_bb0105","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.schres.2008.01.018","article-title":"Predicting antipsychotic drug response \u2014 replication and extension to six weeks in an international olanzapine study","volume":"101","author":"Leucht","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2013.09.015_bb0110","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.biopsych.2010.01.012","article-title":"Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories","volume":"68","author":"Levine","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.09.015_bb0115","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.4088\/JCP.v68n1008","article-title":"Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine","volume":"88","author":"Lin","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.09.015_bb0120","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.psychres.2008.09.004","article-title":"Defining \u201cgood\u201d and \u201cpoor\u201d outcomes in patients with schizophrenia or schizoaffective disorder: a multidimensional data-driven approach","volume":"170","author":"Lipkovich","year":"2009","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pnpbp.2013.09.015_bb0125","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4088\/JCP.v69n0515","article-title":"Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies","volume":"69","author":"Meltzer","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.09.015_bb0130","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1600-0447.2000.tb10933.x","article-title":"Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning","volume":"101","author":"Morosini","year":"2000","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.pnpbp.2013.09.015_bb0135","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1055\/s-2007-1019499","article-title":"The prediction of acute response, remission and general outcome of neuroleptic treatment in acute schizophrenic patients","volume":"16","author":"Nedopil","year":"1983","journal-title":"Pharmacopsychiatria"},{"key":"10.1016\/j.pnpbp.2013.09.015_bb0140","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0165-1781(99)00075-X","article-title":"Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia","volume":"88","author":"Peuskens","year":"1999","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pnpbp.2013.09.015_bb0145","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/hup.1067","article-title":"Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder","volume":"24","author":"Rossi","year":"2009","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2013.09.015_bb0150","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1185\/03007995.2012.708327","article-title":"Flexible dosing with paliperidone ER in the treatment of patients with acutely exacerbated schizophrenia: results from a single-arm, open-label study","volume":"28","author":"Schmauss","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.pnpbp.2013.09.015_bb0155","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0893-133X(02)00375-5","article-title":"Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study","volume":"27","author":"Sechter","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2013.09.015_bb9000","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.pnpbp.2007.06.002","article-title":"Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia","volume":"31","author":"Semiz","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.09.015_bb0165","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/10398560701636963","article-title":"Acute treatment response and its predictors in patients with first-episode psychosis in Iran","volume":"16","author":"Tabatabaee","year":"2008","journal-title":"Australas Psychiatry"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584613002042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584613002042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T16:37:43Z","timestamp":1646671063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584613002042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":32,"alternative-id":["S0278584613002042"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2013.09.015","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of acute schizophrenia with paliperidone ER: Predictors for treatment response and benzodiazepine use","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2013.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}